Navigation Links
Adenoviral vector specifically targeted to EphA2 receptor in pancreatic cancer cells
Date:6/23/2009

Pancreatic cancer is a devastating disease with poor prognosis. This warrants the development of novel therapies including gene therapy. However, clinical studies have demonstrated poor efficacy of adenoviral gene therapy because of the absence of adenoviral binding sites on pancreatic cancer cells such as the coxsackie and adenovirus receptor (CAR). Circumventing CAR-mediated entry therefore seems a promising option to improve adenoviral entry into pancreatic cancer cells and to enhance the efficacy of adenoviral vectors.

A research team led by Dr. Piter J Bosma from University of Amsterdam addressed this question. Their study will be published on June 14, 2009 in the World Journal of Gastroenterology.

They present a novel adenoviral vector that binds to the EphA2 receptor (EphA2R). This receptor is highly expressed in several solid tumors including pancreatic cancer. YSA, a small peptide ligand that binds the EphA2R with high affinity, was inserted into the HI loop of the adenovirus serotype 5 fiber knob. To further increase the specificity of this vector, binding sites for native adenoviral receptors, the coxsackie and adenovirus receptor (CAR) and integrin, were ablated from the viral capsid. The ablated retargeted adenoviral vector was produced on 293T cells. Specific targeting of this novel adenoviral vector to pancreatic cancer was investigated on established human pancreatic cancer cell lines. Upon demonstrating specific in vitro targeting, in vivo targeting to subcutaneous growing human pancreatic cancer was tested by intravenous and intraperitoneal administration of the ablated adenoviral vector.

They found that ablation of native cellular binding sites reduced adenoviral transduction at least 100-fold. Insertion of the YSA peptide in the HI loop restored adenoviral transduction of EphA2R-expressing cells but not of cells lacking this receptor. YSA-mediated transduction was inhibited by addition of synthetic YSA pept
'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. American Medical Association Clears Path for Adenoviral Conjunctivitis - Pink Eye - Detector
2. State Legislature Declares April 21 to 25, 2008 West Nile Virus and Mosquito and Vector Control Awareness Week
3. Non-Profit Healthcare Facilities Invited to Submit Essays in Vector180s Worthy Of Wi-Fi Contest
4. Vaporized viral vector shows promise in anti-cancer gene therapy
5. EaglePicher Technologies Introduces First Implantable Medical Cell Designed Specifically for Monitoring Applications
6. eDiets(R) Partners with alli(R) to Launch Specifically Designed Fresh Meal Delivery Program
7. Paro, the Worlds Only Robotic Baby Harp Seal - Designed Specifically for Therapy - to be Focus of Industry Event at Vinson Hall Retirement Community in McLean, Va., June 2
8. leViv Launches First Meal Programs Specifically Designed for Taste and Health
9. The First Treatment Specifically Approved for Huntingtons Disease Patients is Now Available in the United States
10. Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males
11. First and Only Weaning Product Based on 100% Non-Allergenic Amino-Acids Specifically Designed for Children With Cows Milk Protein Allergy and Multiple Food Protein Intolerance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 The BBB Code ... service practices that enhance customer trust and confidence in ... for Trust, eight principles that summarize important elements of ... represents standards for business accreditation by BBB. Businesses based ... standards and complete application procedures will be accredited by ...
(Date:5/27/2015)... Phoenix, Arizona (PRWEB) May 27, 2015 ... a mission of healthier patients in the community, ... Research Center (formerly John C. Lincoln). SmartPractice Vice President ... Sales Michelle Shaw presented a $25,000 check to Paulla ... at HonorHealth’s Breast Health & Research Center on April ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Allred Dental located ... help patients - who need extensive dental treatment - understand ... treatment options customized for their problems. , Dr. Jeff Allred ... visual presentation of the assessment of the patient’s oral health ... which can treat their oral health problems. , “The dental ...
(Date:5/27/2015)... Black Book Rankings, well known ... the multiple services and software industries, conducted a ... ranked Electronic Health and Medical Record software systems ... focus on implemented EHR users, Black Book reveals ... the highest scores in client experience among small ...
(Date:5/27/2015)... The MedSpa at Hendrick is excited ... treatments in Abilene, Texas: Xeomin®, Belotero Balance® and Radiesse®. ... glabellar lines, better known as the lines between the ... to treat smoker’s lines around the mouth and marionette ... improves the appearance of smile lines or lines around ...
Breaking Medicine News(10 mins):Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:San Marcos Dentistry Office Offering a New Service Dental Case Planning 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2
... it eased shoulder pain caused by osteoarthritis , , THURSDAY, Nov. ... pain in arthritis sufferers, a preliminary study found. , "We ... definitive study," said study author Dr. Jasvinder Singh, a staff ... study was small, and more patients needed to be assessed ...
... have discovered that a molecular switch in the protein making ... common forms of lethal breast cancer worldwide. The discovery by ... therapies for the cancer, called locally advanced breast cancer (LABC)., ... LABC may account for 50 percent or more of breast ...
... out of 250 nationwide in annual ,America,s Best,Health Plans, issue, ... ranking of health plans placed Kaiser Permanente of Georgia first ... 250 plans ranked,nationally., The magazine, on newsstands Nov. 5, ... plans -- making it the top,Medicare plan in the state ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) today announced that ... quarter financial results and to,provide a business update. Anyone ... through a live web-cast. The,teleconference and web-cast information is ... Time: 4:30 p.m. Eastern Standard Time (EST) To ...
... Gregory, the Washington,state man who,s spent more than a year ... expects to conclude his odyssey,today at the southernmost city in ... 2006, Gregory set out from his home near the Canadian,border ... his job,with a beverage distributor to accommodate his plans. His ...
... SEATTLE, Nov. 8 Adaptis, a business ... its majority-owned,company, Tela Sourcing, Inc., has purchased ... onshore mailroom, scanning, EDI and PPO routing,services ... Provider,Organizations (PPOs). (Logo: http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ) ...
Cached Medicine News:Health News:Botox Offers Shot in Arm for Arthritis Sufferers 2Health News:A molecular switch is linked to a common breast cancer 2Health News:U.S. News & World Report Names Kaiser Permanente Top-Ranked Health Plan in Georgia 2Health News:Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update 2Health News:Cross-Country Walker to Finish His Journey for Cancer Research 2Health News:Tela Sourcing, Inc., an Adaptis Company, Acquires HealthASPex Business 2
(Date:5/27/2015)... Conn. , May 27, 2015  With all ... for the services they provide to keep patients healthy ... The ripple effect of the Affordable Care Act continues ... health insurance payer partners, making it more important than ... of communication with those they contract with for patient ...
(Date:5/27/2015)... 2015 The global vitreoretinal surgery ... with analysis and forecast of revenue. This market is ... estimated to grow at a CAGR of 8.9 % ... TOC of the global vitreoretinal surgery devices market report ... This report also provides a glimpse of the market ...
(Date:5/27/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nt9zlx/asia_pacific ) has announced the ... Growth, Trends And Forecasts (2014 - 2019)" company ... detailed type of imaging that customs a low-dose x-ray ... mammogram, is used to support in the early detection ... (radiograph) is a noninvasive medical test that helps physicians ...
Breaking Medicine Technology:Physicians Seek Payer Inclusion, Not Impediment 2Physicians Seek Payer Inclusion, Not Impediment 3Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 3Asia Pacific Mammography Market Trends and Forecasts 2015-2019 2
... NEW YORK, Oct. 27 Intercept Pharmaceuticals, Inc., today ... double-blind Phase II clinical trial of INT-747 in ... evaluated the effects of adding one of three doses ... in patients who did not respond adequately to UDCA ...
... Pharmaceuticals, Inc. today announced $4.5 million in Series A and ... complete the company,s ongoing Phase I/IIa trial of BP-GMAX-CD1 in ... for Phase IIb trials. The company anticipates reporting initial results ... new funding brings the total raised to date to $8.5 ...
Cached Medicine Technology:Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis 2Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis 3Bellicum Pharmaceuticals Announces $4.5 Million in New Funding 2
... Aestiva Excellence for the Induction Room., ... for the Induction Room. The Aestiva/5 Induction ... anesthesia systems, which helps make it easier ... enhanced features include pneumatic gas mixing, O2 ...
... excellence and economy., ,The Aestiva/5 Compact ... basic ventilation at a moderate price. While ... Aestiva/5 Anesthesia System - open architecture, integrated ... a configurable version of Datex-Ohmeda's newest ventilation ...
... patient care., ,S/5 Anesthesia Delivery Unit ... delivery. As part of the S/5 Anesthesia ... controlled gas delivery and agent vaporization with ... a truly integrated system. The S/5 ADUs ...
A non-adhering hydrogel sheet dressing for use on all partial and full thickness wounds (excluding 3rd degree burns.) Hydrogel sheet contains 96% water and 4% insoluble cross-linked polyethylene oxid...
Medicine Products: